A retrospective study of curcumin in combination with intravenous vitamin C (IVC) on triple negative breast cancer(TNBC).

e13118 Background: TNBC is associated with increased mortality compared to other breast cancer sub-types. There is an urgent need to develop novel, low toxicity and effective therapies for TNBC. Methods: Records of 70 advanced triple negative breast cancer patients treated from July 2012 to July 2017 in our hospital were retrospectively analyzed.35 patients received Gemcitabine{day 1 and day 8, 100mg/m2} + Cisplatin{day2,75mg/m2} (control group) and 35 patients received the above chemotherapy regimen in combination with oral curcumin(500mg/d) and IVC{1g/kg.d, starts from the 3rd day when chemotherapy finished,two times a week, totally 15 treatments}(combination group).The effects of the above treatment methods on tumor size, functional status score, progression free survival and overall survival time were analyzed systematically. Results: By using RECIST 1.1 criteria, 2/35 cases had complete remission (CR), 15/35 cases had partial remission (PR) and 13/35 cases had stable disease (SD) in the treatment group. The response rate(RR) was 49%. In the control group, there were no CR cases, 14 cases had PR, 14 cases had SD, the RR was 40%. There was no significant difference in RR between the two groups(P > 0.05). The median progression free survival time(PFS) and median overall survival time(OS) was 7 months (95% CI:1.5 to 28.5 months) and 27 months (95% CI:4 to 40 months) in the combination group compared with 4.5 months (95% CI:1.5 to 8 months) and 18 months (95% CI:3 to 26 months) in the control group. Kaplan-Meier survival analysis revealed that both PFS and OS in the combination group were significantly longer than that in the control group. (P < 0.05). All patients experienced adverse reaction in GI tract and myelosuppression. The incidence of adverse reactions in the treatment group was significantly lower than that of the control group. (P < 0.05). Conclusions: Although there was no significant difference in short-term efficacy between the two groups,this study suggested that curcumin supplementation in combination with IVC can be used during chemotherapy to reduce adverse reactions. Moreover, it helps to prolong PFS and OS of patients with late stage triple-negative breast cancer.